Cargando…

Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-negative Organisms Causing Bloodstream Infections Worldwide

BACKGROUND: Zidebactam (ZID), a bicyclo-acyl hydrazide, is a β-lactam enhancer with a dual mechanism of action involving selective and high binding affinity to Gram-negative (GN) PBP2 and β-lactamase inhibition. We evaluated the in vitro activity of cefepime (FEP) combined with ZID against GN organi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sader, Helio S, Castanheira, Mariana, Streit, Jennifer M, Duncan, Leonard R, Flamm, Robert K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631344/ http://dx.doi.org/10.1093/ofid/ofx163.922

Ejemplares similares

2214. Comparison of Cefepime–Zidebactam (WCK 5222), Ceftazidime–Avibactam, and Ceftolozane–Tazobactam Tested Against Gram-Negative Organisms Causing Pneumonia in United States Hospitals in 2018
por: Sader, Helio S, et al.
Publicado: (2019)

1598. Antimicrobial Activity of the Novel β-Lactam Enhancer Combination Cefepime–Zidebactam (WCK-5222) Tested Against Gram-Negative Bacteria Isolated in United States Medical Centers from Patients with Bloodstream Infections
por: Castanheira, Mariana, et al.
Publicado: (2019)

Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate
por: Pan, Xiaolei, et al.
Publicado: (2022)

725. WCK 5222 (Cefepime/Zidebactam): An In Vitro Assessment of Activity Compared with Current Dual-Antibiotic Options Against Multidrug-Resistant Pseudomonas aeruginosa
por: Mullane, Elias M, et al.
Publicado: (2019)

1336. Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenems-Resistant Acinetobacter baumannii (CR-ACBN) in the Neutropenic Murine Thigh Infection Model
por: Abuhussain, Safa Almarzoky, et al.
Publicado: (2018)

675. Efficacy of Human-Simulated Bronchopulmonary Exposures of Cefepime and Zidebactam (WCK 5222) Against Multidrug-Resistant (MDR) Pseudomonas aeruginosa (PSA) in a Neutropenic Murine Pneumonia Model
por: Kidd, James M, et al.
Publicado: (2019)

685. An In Vitro Investigation of WCK 5222 (Cefepime/Zidebactam) and Currently Available Combination Antibiotic Regimens Against Enterobacteriaceae That Co-express Serine-β-Lactamase (SBL) and Metallo-β-Lactamase (MBL) Enzymes
por: Avery, Lindsay M, et al.
Publicado: (2019)

Activity of Cefepime-Zidebactam against Multidrug-Resistant (MDR) Gram-Negative Pathogens
por: Thomson, Kenneth S., et al.
Publicado: (2019)

Activity of ertapenem/zidebactam (WCK 6777) against problem Enterobacterales
por: Mushtaq, Shazad, et al.
Publicado: (2022)

Case Commentary: Successful Use of Cefepime/Zidebactam (WCK 5222) as a Salvage Therapy for the Treatment of Disseminated Extensively Drug-Resistant New Delhi Metallo-β-Lactamase-Producing Pseudomonas aeruginosa Infection in an Adult Patient with Acute T-Cell Leukemia
por: Egge, Stephanie L., et al.
Publicado: (2023)

Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report
por: Dubey, Dilip, et al.
Publicado: (2023)

In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model
por: Gethers, Matthew, et al.
Publicado: (2022)

In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2023)

2427. Comparison of Ceftazidime–Avibactam and Ceftolozane-Tazobactam In Vitro Activities When Tested Against Gram-Negative Bacteria Isolated From Patients Hospitalized With Pneumonia in US Medical Centers (2017)
por: Sader, Helio S, et al.
Publicado: (2018)

1436. Comparison of Ceftazidime–Avibactam, Ceftolozane–Tazobactam, Piperacillin–Tazobactam, and Meropenem Activities When Tested Against Gram-Negative Organisms Isolated From Complicated Urinary Tract Infections
por: Sader, Helio S, et al.
Publicado: (2019)

Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019)
por: Carvalhaes, Cecilia G., et al.
Publicado: (2022)

1523. Antimicrobial Activity of Ceftazidime–Avibactam and Comparator Agents Tested Against Gram-Negative Organisms Isolated from Complicated Urinary Tract Infections: Results from the International Network for Optimal Resistance Monitoring (INFORM) Program
por: Sader, Helio S, et al.
Publicado: (2018)

129. Antimicrobial Activity of Ceftazidime–avibactam and Comparator Agents Tested against Gram-Negative Organisms Isolated from Patients with Bloodstream Infections in United States Medical Centers (2017–2018)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)

In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates
por: Le Terrier, Christophe, et al.
Publicado: (2023)

Broad In Vitro Activity Analysis of Tedizolid Compared with Other Agents against a Global Collection of Gram-Positive Isolates Causing Bloodstream Infections (2014–2016)
por: Mendes, Rodrigo E, et al.
Publicado: (2017)

2192. Comparative Antimicrobial Susceptibility of Gram-Negative Bacteria Isolated from Patients with Bloodstream Infections and Pneumonia when Tested against Tazobactam Combinations
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)

1004. Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated From Patients Hospitalized With Bloodstream Infections in United States Medical Centers (2015–2017)
por: Sader, Helio S, et al.
Publicado: (2018)

1308. Activity of Cefiderocol and Comparators against Gram-negative Isolates from US Patients Hospitalized with Pneumonia
por: Shortridge, Dee, et al.
Publicado: (2021)

212. Effectiveness of Empirical Piperacillin/tazobactam Compared to Cefepime for Bloodstream Infection Caused by Gram-Negative Bacilli
por: Ho Lee, Young, et al.
Publicado: (2023)

1245. In Vivo Efficacy of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) Against β-Lactamase-Producing (BLP) Gram-Negative Bacteria in a Neutropenic Murine Pneumonia Model
por: Lasko, Maxwell J, et al.
Publicado: (2020)

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Enterobacteriaceae and Pseudomonas aeruginosa from United States (US) Medical Centers Stratified by Infection Type (2015–2016)
por: Sader, Helio S, et al.
Publicado: (2017)

2598. Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations against Gram-negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2020–2022)
por: Sader, Helio S, et al.
Publicado: (2023)

1620. Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens
por: Shorttidge, Dee, et al.
Publicado: (2020)

238. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients with Bone and Joint Infections from the United States (US) and Europe (2016-2020): Results from the International Dalbavancin Evaluation of Activity (IDEA) Program
por: Sader, Helio S, et al.
Publicado: (2021)

26. in Vitro selection Of enterobacter Cloacae with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanism
por: Castanheira, Mariana, et al.
Publicado: (2020)

1629. Vancomycin Resistance in Enterococcus faecium Clinical Isolates Responsible for Bloodstream Infections in US Hospitals Over Ten Years (2010-2019) and Activity of Oritavancin
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

333. Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015–2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2020)

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014–2016)
por: Mendes, Rodrigo E, et al.
Publicado: (2017)

Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020)
por: Sader, Helio S., et al.
Publicado: (2022)

1000. Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated From Patients Hospitalized With Bacteremia in United States and European Medical Centers: Results From the International Dalbavancin Evaluation of Activity (IDEA) Program
por: Sader, Helio S, et al.
Publicado: (2018)

1949. Activity of Aztreonam-Avibactam against Enterobacterales Resistant to Recently Approved Beta-Lactamase Inhibitor Combinations Collected Worldwide (ex-US; 2020–2022)
por: Sader, Helio S, et al.
Publicado: (2023)

In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions
por: Pfaller, Michael A., et al.
Publicado: (2017)

Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)
por: Flamm, Robert K, et al.
Publicado: (2017)

Activity of Meropenem-Vaborbactam Against Enterobacteriaceae Isolates Carrying bla(KPC) Collected Worldwide
por: Castanheira, Mariana, et al.
Publicado: (2017)

646. Activity of Oritavancin and Comparator Agents Against Coagulase-negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vkia2cp05du9ko1i0u17d78ou7